Algert Global LLC reduced its holdings in shares of Addus Homecare Co. (NASDAQ:ADUS) by 62.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 17,974 shares of the company’s stock after selling 29,554 shares during the quarter. Algert Global LLC owned 0.14% of Addus Homecare worth $1,261,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in the stock. Smith Asset Management Group LP purchased a new stake in shares of Addus Homecare during the second quarter worth about $1,439,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Addus Homecare during the 2nd quarter valued at about $378,000. First Trust Advisors LP grew its stake in Addus Homecare by 18.9% during the 2nd quarter. First Trust Advisors LP now owns 8,480 shares of the company’s stock valued at $485,000 after acquiring an additional 1,347 shares in the last quarter. Engineers Gate Manager LP purchased a new stake in Addus Homecare during the 2nd quarter valued at about $384,000. Finally, Rhumbline Advisers grew its stake in Addus Homecare by 14.5% during the 2nd quarter. Rhumbline Advisers now owns 7,630 shares of the company’s stock valued at $437,000 after acquiring an additional 964 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.
In other news, Director Mark L. First sold 352,400 shares of the stock in a transaction that occurred on Tuesday, November 27th. The shares were sold at an average price of $72.60, for a total value of $25,584,240.00. Following the completion of the sale, the director now owns 19,151 shares of the company’s stock, valued at approximately $1,390,362.60. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Laurie Manning sold 1,000 shares of the stock in a transaction that occurred on Monday, November 19th. The shares were sold at an average price of $71.91, for a total transaction of $71,910.00. Following the completion of the sale, the executive vice president now directly owns 11,537 shares of the company’s stock, valued at approximately $829,625.67. The disclosure for this sale can be found here. In the last three months, insiders sold 923,400 shares of company stock valued at $66,935,850. Corporate insiders own 34.80% of the company’s stock.
Shares of NASDAQ ADUS opened at $74.40 on Friday. Addus Homecare Co. has a 12-month low of $31.67 and a 12-month high of $77.82. The stock has a market cap of $999.93 million, a P/E ratio of 51.31, a price-to-earnings-growth ratio of 3.02 and a beta of -0.27. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.19 and a quick ratio of 4.19.
Addus Homecare (NASDAQ:ADUS) last announced its quarterly earnings data on Tuesday, November 6th. The company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.40 by $0.08. Addus Homecare had a net margin of 3.25% and a return on equity of 9.55%. The company had revenue of $137.63 million during the quarter, compared to analysts’ expectations of $139.43 million. As a group, equities analysts forecast that Addus Homecare Co. will post 1.69 earnings per share for the current year.
ADUS has been the subject of several research reports. ValuEngine raised shares of Addus Homecare from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 4th. BidaskClub cut shares of Addus Homecare from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 10th. Jefferies Financial Group initiated coverage on shares of Addus Homecare in a research note on Tuesday, August 21st. They set a “buy” rating and a $75.00 price objective for the company. Oppenheimer upped their price objective on shares of Addus Homecare from $72.00 to $80.00 and gave the company an “outperform” rating in a research note on Wednesday, November 7th. Finally, Zacks Investment Research cut shares of Addus Homecare from a “hold” rating to a “strong sell” rating in a research note on Monday, August 13th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Addus Homecare presently has an average rating of “Buy” and a consensus target price of $73.50.
TRADEMARK VIOLATION NOTICE: “Addus Homecare Co. (ADUS) Position Decreased by Algert Global LLC” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2018/12/08/addus-homecare-co-adus-position-decreased-by-algert-global-llc.html.
Addus Homecare Profile
Addus HomeCare Corporation provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company's personal care services offer assistance with activities of daily living. Its services include assistance with bathing, grooming, oral care, assistance with feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services, as well as other activities of daily living.
Featured Story: How interest rates affect municipal bond prices
Want to see what other hedge funds are holding ADUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Addus Homecare Co. (NASDAQ:ADUS).
Receive News & Ratings for Addus Homecare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addus Homecare and related companies with MarketBeat.com's FREE daily email newsletter.